Provectus Biopharmaceuticals (PVCT) 10-K 2 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 28, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 16,529,509
Entity Common Stock, Shares Outstanding		403,557,037
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 97,231	$ 590,706
Short-term receivables - legal fees, settlement and other, net	3,930	55,058
Prepaid expenses	322,518	350,249
Total Current Assets	423,679	996,013
Equipment and furnishings, less accumulated depreciation of $78,313 and $64,630, respectively	44,701	58,384
Operating lease right-of-use asset	120,821	194,400
Patents, net of accumulated amortization of $11,715,455 and $11,487,338, respectively		228,107
Total Assets	589,201	1,476,904
Current Liabilities:
Accounts payable - trade	956,860	1,125,890
Other accrued expenses	1,500,782	1,026,842
Current portion of accrued interest	2,774,968	65,333
Current portion of accrued interest - related parties	1,766,493
Current portion of note payable	236,228	228,423
Current portion of convertible notes payable	16,622,000	500,000
Current portion of convertible notes payable - related parties	6,770,000
Current portion of operating lease liability	84,383	76,423
Total Current Liabilities	30,711,714	3,022,912
Accrued interest, non-current portion		1,501,864
Accrued interest, non-current portion - related parties		1,226,582
Note payable, non-current portion	39,061
Convertible notes payable, non-current portion		12,997,000
Convertible notes payable, non-current portion - related parties		6,670,000
Operating lease liability, non-current portion	44,783	130,658
Total Liabilities	30,795,558	25,549,016
Commitments and contingencies (Note 11)
Stockholders' Deficiency:
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at December 31, 2020 and December 31, 2019; aggregate liquidation preference of $3,500 at December 31, 2020 and December 31, 2019
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 398,807,037 and 389,889,475 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	398,808	389,889
Additional paid-in capital	209,923,347	209,378,835
Accumulated other comprehensive loss	(34,097)	(24,008)
Accumulated deficit	(240,494,415)	(233,816,828)
Total Stockholders' Deficiency	(30,206,357)	(24,072,112)
Total Liabilities and Stockholders' Deficiency	$ 589,201	$ 1,476,904

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accumulated depreciation on equipment and furnishings	$ 78,313	$ 64,630
Accumulated amortization on patents	$ 11,715,455	$ 11,487,338
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Aggregate liquidation preference	$ 3,500	$ 3,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	398,807,037	389,889,475
Common stock, shares outstanding	398,807,037	389,889,475
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Expenses:
Research and development	$ 2,812,760	$ 4,002,014
General and administrative	2,150,816	2,297,682
Total Operating Expenses	4,963,576	6,299,696
Total Operating Loss	(4,963,576)	(6,299,696)
Other Income/(Expense):
EIDL grant	3,000
Gain on settlement of lawsuits		675,000
Research and development tax credit	27,694	134,081
Investment and interest income	3,415	23,162
Interest expense	(1,748,120)	(1,455,084)
Total Other Expense, Net	(1,714,011)	(622,841)
Net Loss	$ (6,677,587)	$ (6,922,537)
Basic and Diluted Loss Per Common Share	$ (0.02)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	393,252,321	386,593,634

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Net Loss	$ (6,677,587)	$ (6,922,537)
Other Comprehensive Loss:
Foreign currency translation adjustments	(10,089)	(24,008)
Total Comprehensive Loss	$ (6,687,676)	$ (6,946,545)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficiency - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Preferred Stock Series B [Member]
Beginning Balance
Beginning Balance, shares	100	100
Common stock issued upon exercise of warrants
Common stock issued upon exercise of warrants, shares
Stock-based compensation: Option
Stock-based compensation: Common stock
Stock-based compensation: Common stock, shares
Stock-based compensation: Warrants
Net loss
Other comprehensive loss
Ending Balance
Ending Balance, shares	100	100
Common Stock [Member]
Beginning Balance	$ 389,889	$ 384,615
Beginning Balance, shares	389,889,475	384,614,528
Common stock issued upon exercise of warrants	$ 7,856	$ 5,045
Common stock issued upon exercise of warrants, shares	7,855,062	5,045,857
Stock-based compensation: Option
Stock-based compensation: Common stock	$ 1,063	$ 229
Stock-based compensation: Common stock, shares	1,062,500	229,090
Stock-based compensation: Warrants
Net loss
Other comprehensive loss
Ending Balance	$ 398,808	$ 389,889
Ending Balance, shares	398,807,037	389,889,475
Additional Paid-In Capital [Member]
Beginning Balance	$ 209,378,835	$ 209,092,187
Common stock issued upon exercise of warrants	410,821	263,898
Stock-based compensation: Option	64,294
Stock-based compensation: Common stock	68,025	11,309
Stock-based compensation: Warrants	1,372	11,441
Net loss
Other comprehensive loss
Ending Balance	209,923,347	209,378,835
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(24,008)
Common stock issued upon exercise of warrants
Stock-based compensation: Option
Stock-based compensation: Common stock
Stock-based compensation: Warrants
Net loss
Other comprehensive loss	(10,089)	(24,008)
Ending Balance	(34,097)	(24,008)
Accumulated Deficit [Member]
Beginning Balance	(233,816,828)	(226,894,291)
Common stock issued upon exercise of warrants
Stock-based compensation: Option
Stock-based compensation: Common stock
Stock-based compensation: Warrants
Net loss	(6,677,587)	(6,922,537)
Other comprehensive loss
Ending Balance	(240,494,415)	(233,816,828)
Beginning Balance	(24,072,112)	(17,417,489)
Common stock issued upon exercise of warrants	418,677	268,943
Stock-based compensation: Option	64,294
Stock-based compensation: Common stock	69,088	11,538
Stock-based compensation: Warrants	1,372	11,441
Net loss	(6,677,587)	(6,922,537)
Other comprehensive loss	(10,089)	(24,008)
Ending Balance	$ (30,206,357)	$ (24,072,112)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (6,677,587)	$ (6,922,537)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	134,754	22,979
Noncash lease expense	73,579	71,150
Depreciation	13,683	14,092
Amortization of patents	228,107	671,120
Changes in operating assets and liabilities
Short term receivables	50,321	4,907
Prepaid expenses	347,107	19,960
Accounts payable - trade	(170,413)	(2,186,159)
Other accrued expenses	244,887	731,134
Operating lease liability	(77,916)	(71,945)
Accrued interest expense	1,747,683	1,455,084
Net Cash Used In Operating Activities	(4,085,795)	(6,190,215)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	3,125,000	6,435,000
Proceeds from issuance of convertible notes payable - related parties	100,000	50,000
Repayment of short-term note payable	(105,985)
Proceeds from note payable	62,500
Proceeds from exercise of warrants	418,676	268,943
Net Cash Provided By Financing Activities	3,600,191	6,753,943
Effect of Exchange Rate Changes on Cash	(7,871)	(24,008)
Net (Decrease)/Increase In Cash and Cash Equivalents	(493,475)	539,720
Cash and Cash Equivalents, Beginning of Period	590,706	50,986
Cash and Cash Equivalents, End of Period	97,231	590,706
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Purchase of insurance policies financed by short-term note payable	318,775	319,102
Offset of related party receivable and payable		$ 535,361

Business Organization and Natur

Business Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	1. Business Organization and Nature of Operations Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, with the aim of maximizing the curative impact of these medicines and achieving immunity from treated disease. These investigational drugs are based on an entire, wholly-owned, family of small molecules called halogenated xanthenes (“HXs”); our lead HX molecule is named rose bengal disodium (“RBD”). ● Oncology: ® Oral formulations of cGMP RBD are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers. ● Pediatric Oncology: ● Hematology: ● Virology: ● Microbiology: ● Ophthalmology: ● Dermatology: ® To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at December 31, 2020. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash and cash equivalents were $97,231 at December 31, 2020, compared with $590,706 at December 31, 2019. The Company continues to incur significant operating losses and management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10 and PH-10 and raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2020 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2020 Financing or otherwise, it will not be able to pay its obligations as they become due. Subsequent to December 31, 2020, the Company received an aggregate $1,200,000 in connection with the 2020 Financing. In addition, holders of 4,500,000 warrants to purchase the common stock of the Company at $0.0533 per share, have exercised these warrants, resulting in aggregate proceeds to the Company in the amount of $239,850. See Note 14 – Subsequent Events. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company, or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2021 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2020 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the collectability of receivables, the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2020 and 2019, the Company’s cash equivalent consists of Treasury bills. Cash Concentrations Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future. Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers, leasehold improvements and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets. Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2020 and 2019. Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are fully amortized. Annual amortization of the patents was $228,000 in 2020. Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 7 – Short-term Receivables. Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2020 or 2019. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2020 2019 Warrants 87,264,164 126,109,532 Options 4,800,000 3,000,000 Convertible preferred stock 65,663 65,663 Total potentially dilutive shares 92,129,827 129,175,195 The potential dilutive effect of the conversion of the Company’s convertible notes payable has been excluded from this table since the Company’s Series D Preferred Stock has yet to be designated by the Board. Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2020 and 2019. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, receivables, other current assets, accounts payable, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($10,552 and $332,446 at December 31, 2020 and $61,380 and $308,915 at December 31, 2019, respectively), and expense and other income accounts are translated at a weighted average exchange rate for the years then ended ($44,994 and $53,210 for the years ended December 31, 2020 and 2019, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive loss (“AOCL”), which is a separate component of shareholders’ deficit. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denomination transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s consolidated financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its consolidated financial statements and related disclosures. In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. The Company is currently evaluating the effect of the adoption of ASU 2020-06 will have on its consolidated financial statements and related disclosures. In October 2020, the FASB issued ASU 2020-10 “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance is effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company is currently assessing the impact that this pronouncement will have on its consolidated financial statements. Recent Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted ASU effective January 1, 2020 and it did not have a material impact on the consolidated financial statements. Reclassifications Certain prior period amounts have been reclassified for comparative purposes to conform with the fiscal 2020 presentation. These reclassifications have no impact on the previously reported net loss.

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	4. Convertible Notes Payable 2017 Financing On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company’s stockholders (the “PRH Group”), which was amended and restated effective as of March 19, 2017 (the “2017 Term Sheet”) that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $10,000,000 and maximum of $20,000,000 (the “2017 Financing”). As of December 31, 2020, the Company had received aggregate 1st Loans, as defined below, of $20,067,000 in connection with the 2017 Financing. The 2017 Financing is in the form of a secured convertible loan (the “1 st st st st (i) It is secured by a first priority security interest on the Company’s IP, (ii) The 1 st (iii) The 1 st (iv) The 2017 Notes, including interest and principal, are due and payable in full on the earlier of: (i) on such date upon which the Company defaults under the 2017 Notes, (ii) upon a change of control of the Company, or (iii) dates ranging from May 15, 2021 to the 18-month anniversary of the funding of the Final Tranche. In the event there is a change of control of the Company’s Board as proposed by any person or group other than the 1 st st (v) The outstanding principal amount and interest payable under the 1 st 1 st (vi) Notwithstanding (v) above, the principal amount of the 2017 Notes and the interest payable under the 1 st Pursuant to the 2017 Term Sheet, the PRH Group concluded its best-efforts activity to arrange for a financing of $20,000,000, which amounts were provided in a number of tranches, between the first tranche on April 4, 2017 and the Final Tranche, on December 20, 2019. As a result, the 2017 Notes under the 1 st Upon conversion of the 2017 Notes, the 1 st 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $20,000,000 (the “2020 Financing”). The 2020 Financing will be in the form of secured convertible loans from investors that will be evidenced by convertible promissory notes (the “2020 Notes”). The 2020 Term Sheet is similar to the 2017 Term Sheet. Subject to the terms and conditions of the 2020 Term Sheet, the Company will use its best efforts to arrange for the 2020 Financing, which amounts will be obtained in several tranches. The proceeds from the 2020 Financing will be used to fund the Company’s clinical development program, as currently constituted and envisioned, and to fund the Company’s general and administrative expenses. Pursuant to the 2020 Term Sheet, the 2020 Notes (defined below) will convert into shares of the Company’s Series D Preferred Stock on or before June 20, 2021, subject to certain exceptions. As of December 31, 2019, and through the date of filing, the Series D Preferred Stock had not been designated by the Board. The 2020 Financing will be in the form of a secured convertible loan (the “2 nd (the “2 nd (i) It will be secured by a second priority security interest on the Company’s IP subordinate to the first priority security interest of the 2017 Notes; (ii) The 2 nd nd (iii) In the event there is a change of control of the Company’s Board, the term of the 2020 Notes will be accelerated and all amounts due under the 2020 Notes will be immediately due and payable, plus interest at the rate of eight percent (8%) per annum, plus a penalty in the amount equal to ten times (10x) the outstanding principal amount of the 2 nd (iv) The outstanding principal amount and interest payable under the 2 nd nd (v) Notwithstanding (iv) above, the principal amount of the 2020 Notes and the interest payable under the 2 nd Upon conversion of the 2 nd nd nd pari passu st Since the 2020 Financing was launched and through December 31, 2020, the Company had received aggregate 2 nd Convertible Notes Payable – Related Parties During the year ended December 31, 2019, the Company entered into 2017 Notes with related parties in the aggregate principal amount of $50,000 offset by the application of the 2017 Note in the principal amount of $250,000 that the Company entered into with Timothy Scott (former President) and Leigh Anne Scott on February 28, 2018 that was applied to Dr. Scott’s Kleba Settlement agreement. As of December 31, 2020 and 2019, the Company had borrowed $6,670,000 of 2017 Notes from related parties which were outstanding. During the year ended December 31, 2020, the Company entered into 2020 Notes with related parties in the aggregate principal amount of $100,000. As of December 31, 2020, the Company had borrowed $100,000 of 2020 Notes from related parties which were outstanding. Convertible Notes Payable – Non-Related Parties During the year ended December 31, 2019, the Company entered into 2017 Notes with accredited investors in the aggregate principal amount of $6,335,000. As of December 31, 2020 and 2019, the Company had borrowed $13,397,000 under these notes, all of which were outstanding as of that date. During the year ended December 31, 2019, the Company entered into a 2020 Note with an accredited investor in the principal amount of $100,000. As of December 31, 2019, the Company had borrowed $100,000 under this note. During the year ended December 31, 2020, the Company entered into 2020 Notes with accredited investors in the aggregate principal amount of $3,125,000. As of December 31, 2020, the Company had borrowed $3,225,000 under these notes, all of which were outstanding as of that date. The Series D Preferred Stock As of December 31, 2020, and through the date of filing, the Series D Preferred Stock had not been designated by the Board. Per the terms of the notes issued in connection with the 2017 and 2020 Financings, if the Company has not designated the Series D Preferred Stock or if an insufficient number of Series D Preferred shares exist upon a conversion by a note holder, then the outstanding loans will continue to accrue interest at a rate of 8% per annum until which time the Company has designated a sufficient number of Series D Preferred shares. As a result, the Company did not analyze the notes for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the notes were not convertible as of their respective dates of issuance or as of December 31, 2020.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable On April 20, 2020, the Company received a $62,500 loan under the CARES Act PPP (the “PPP Loan”). The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. The loan principal and accrued interest are forgivable, as long as the borrower uses loan proceeds for eligible uses during a specified period following disbursement, such as payroll, benefits, rent, and utilities, and maintains specified headcount and payroll thresholds. If any portion of a PPP Loan is not forgiven, the unforgiven portion is payable over two years at an interest rate of 1%, with a deferral of payments for the first seven months. The Company intends to use PPP Loan proceeds in a manner that it believes presently qualifies for full forgiveness. We cannot provide assurance that the PPP Loan will be forgiven in full. As of December 31, 2020, the Company had not applied for forgiveness of the PPP Loan. Once an amount is forgiven under the PPP Loan, the Company will recognize a gain on forgiveness of note payable in the period in which it obtained forgiveness. The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of December 31, 2020 and 2019, the balance of the note payable was $212,790 and $228,424, respectively.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions During the years ended December 31, 2020 and 2019, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $254,400 and $277,200, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of December 31, 2020 and 2019 were $75,000 and $75,000, respectively. Mr. Horowitz serves as both COO and a Director. See Note 4 and Note 7 for details of other related party transactions. Director fees during the years ended December 31, 2020 and 2019 were $383,065 and $385,000, respectively. Accrued directors’ fees as of December 31, 2020 and 2019 were $1,175,589 and $792,524, respectively.

Short-Term Receivables

Short-Term Receivables	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Short-Term Receivables	7. Short-term Receivables The following table summarizes the receivables at December 31, 2020 and 2019: December 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia tax credit $ 3,930 $ - $ - $ 3,930 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 3,930 $ - $ - $ 3,930 December 31, 2019 Legal Fees Legal Fees Settlement Total Provectus Australia tax credit $ 55,058 $ - $ - $ 55,058 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 55,058 $ - $ - $ 55,058 During the year ended December 31, 2019, officers of the Company offset their settlement amounts owed to the Company against accrued payroll and other payables totaling $535,361. This offset reduced the amount of the settlement and was approved by the Company’s Board.

Stockholders' Deficiency

Stockholders' Deficiency	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Deficiency	8. Stockholders’ Deficiency Authorized Capital As of December 31, 2020, the Company was authorized to issue 1,000,000,000 shares of common stock, $0.001 par value, and 25,000,000 shares of preferred stock, $0.001 par value. The holders of the Company’s common stock are entitled to one vote per share. The preferred stock is designated as follows: 240,000 shares to Series B Convertible Preferred Stock (the “Series B Preferred Stock”) and 24,760,000 shares undesignated. Series B Convertible Preferred Stock On August 25, 2016, the Company filed the Series B Certificate of Designation with the Delaware Secretary of State. The Series B Certificate of Designation provides for the issuance of the Series B Preferred Stock, par value $0.001 per share. In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Preferred Stock will be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series B Preferred Stock if such shares had been converted to common stock immediately prior to such event (without giving effect for such purposes to any beneficial ownership limitation), subject to the preferential rights of holders of any class or series of the Company’s capital stock specifically ranking by its terms senior to the Series B Preferred Stock as to distributions of assets upon such event, whether voluntarily or involuntarily. The Series B Preferred Stock has no voting rights. The holders of Series B Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 8% per annum of the stated value per share, until the fifth anniversary of the date of issuance of the Series B Preferred Stock. The dividends become payable, at the Company’s option in either cash, out of any funds legally available for such purpose, or in shares of common stock, (i) upon any conversion of the Series B Preferred Stock, (ii) on each such other date as the Board may determine, subject to written consent of the holders of Series B Preferred Stock holding a majority of the then issued and outstanding Series B Preferred Stock, (iii) upon the Company’s liquidation, dissolution or winding up, and (iv) upon occurrence of a fundamental transaction, which includes any merger or consolidation, sale of all or substantially all of the Company’s assets, exchange or conversion of all of the common stock by tender offer, exchange offer or reclassification; provided, however, that if Series B Preferred Stock is converted into shares of common stock at any time prior to the fifth anniversary of the date of issuance of the Series B Preferred Stock, the holder will receive a make-whole payment in an amount equal to all of the dividends that, but for the early conversion, would have otherwise accrued on the applicable shares of Series B Preferred Stock being converted for the period commencing on the conversion date and ending on the fifth anniversary of the date of issuance, less the amount of all prior dividends paid on such converted Series B Preferred Stock before the date of conversion. Make-whole payments are payable at the Company’s option in either cash, out of any funds legally available for such purpose, or in shares of common stock. With respect to any dividend payments and make-whole payments paid in shares of common stock, the number of shares of common stock to be issued to a holder of Series B Preferred Stock will be an amount equal to the quotient of (a) the amount of the dividend payable to such holder divided by (b) the conversion price then in effect. Common Stock Issuances During the year ended December 31, 2019, the Company issued 229,090 shares of immediately vested restricted common stock as payment of services, with an aggregate issuance date fair value of $11,538, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statement of operations. During the year ended December 31, 2020, the Company issued 1,062,500 shares of immediately vested restricted common stock with an aggregate issuance date value of $69,088 , which was recognized immediately as stock compensation within general and administrative expenses on the accompanying consolidated statement of operations.

Stock Incentive Plan and Warran

Stock Incentive Plan and Warrants	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Incentive Plan and Warrants	9. Stock Incentive Plan and Warrants The 2017 Amendment and Restatement of the Provectus Biopharmaceuticals, Inc. 2014 Equity Compensation Plan (the “2017 Equity Compensation Plan”) provides for the issuance of up to 20,000,000 shares of common stock pursuant to stock options for the benefit of eligible employees and directors of the Company. Options granted under the 2017 Equity Compensation Plan are either “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code or options which are not incentive stock options. The stock options are exercisable over a period determined by the Board of Directors (through its Compensation Committee), but generally no longer than 10 years after the date they are granted. As of December 31, 2020, there were 15,312,500 shares available for issuance under the 2017 Equity Compensation Plan. There were no stock options granted during the year ended December 31, 2019. During the year ended December 31, 2020, the Company issued 2,425,000 five-year immediately vested stock options to an officer/director to purchase an aggregate of 2,425,000 shares of common stock with exercise price of $0.12 per share. The stock options had an aggregate grant date fair value of $62,880, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying statement of operations. During the year ended December 31, 2020, the Company issued 100,000 five-year immediately vested stock options to a director to purchase an aggregate of 100,000 shares of common stock with an exercise price of $0.2862 per share. The stock options had an aggregate grant date fair value of $1,414, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying statement of operations. Stock Options granted during the year ended December 31, 2020 were valued using the Black Scholes Model, with the following assumptions used: For the Years Ended December 31, 2020 2019 Expected terms (years) 2.50 - Expected volatility 93 % - Risk-free interest rate 0.23 % - Expected dividend 0.00 % - The following table summarizes option activity during the year ended December 31, 2020 and 2019: Weighted Average Options Exercise Price Outstanding and exercisable at January 1, 2019 3,200,000 $ 0.89 Granted - - Exercised - - Forfeited (200,000 ) 0.88 Outstanding and exercisable at December 31, 2019 3,000,000 $ 0.88 Granted 2,525,000 .20 Exercised - - Forfeited (725,000 ) 0.88 Outstanding and exercisable at December 31, 2020 4,800,000 $ 0.46 The following table summarizes information about stock options outstanding at December 31, 2020. Number Outstanding Weighted Average Number Exercisable Exercise Price at December 31, 2020 Life at December 31, 2020 $ 0.12 2,425,000 4.90 2,425,000 $ 0.29 100,000 4.90 100,000 $ 0.67 200,000 2.60 200,000 $ 0.75 950,000 3.11 950,000 $ 0.84 150,000 1.50 150,000 $ 0.88 150,000 3.60 150,000 $ 0.93 575,000 0.76 575,000 $ 0.99 50,000 0.50 50,000 $ 1.04 200,000 0.50 200,000 4,800,000 3.58 4,800,000 As of December 31, 2020, the intrinsic value of outstanding and exercisable options was $0. Warrants During the year-ended December 31, 2019, holders of warrants exercised warrants to purchase 5,045,857 shares of common stock at a price of $0.053 per share. In connection with the exercises, the Company received cash proceeds of $268,943 and issued 5,045,857 shares of common stock. During the year ended December 31, 2020, holders of warrants exercised warrants to purchase 7,855,062 shares of common stock at a price of $0.053 per share. In connection with the exercises, the Company received cash proceeds of $418,676 and issued 7,855,062 shares of common stock. During the year ended December 31, 2020, the Company issued 62,500 three-year immediately vested warrants to board members to purchase an aggregate of 62,500 shares of common stock with an exercise price of $0.2862 per share. The warrants had an aggregate grant date fair value of $1,372, which was recognized immediately as stock compensation within general and administrative expenses on the accompanying statement of operations. In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Years Ended December 31, 2020 2019 Contractual terms (years) 3.00 3.00-5.00 Expected volatility 93%-95 % 129%-131 % Risk-free interest rate .011%-0.18 % 1.82%-2.33 % Expected dividend 0.00 % 0.00 % The following table summarizes warrant activity during the year ended December 31, 2020 and 2019: Weighted Average Warrants Exercise Price Outstanding and exercisable at January 1, 2019 136,824,138 $ 0.27 Granted 425,000 0.94 Exercised (5,045,857 ) 0.05 Forfeited (6,093,749 ) 1.20 Outstanding and exercisable at December 31, 2019 126,109,532 $ 0.29 Granted 62,500 0.29 Exercised (7,855,062 ) 0.05 Forfeited (31,052,806 ) 1.06 Outstanding and exercisable at December 31, 2020 87,264,164 $ 0.02 The following table summarizes information about warrants outstanding at December 31, 2020. Number Outstanding Weighted Average Number Exercisable Intrinsic Value at December 31, Remaining Contractual at December 31, at December 31, Exercise Price 2020 Life 2020 2020 $ 0.05 86,776,664 0.66 86,776,664 $ 407,850 $ 0.29 100,000 2.30 100,000 $ - $ 1.00 18,000 3.39 18,000 $ - $ 1.12 366,000 3.38 366,000 $ - $ 2.00 3,500 3.38 3,500 $ - 87,264,164 2.62 87,264,164 $ 407,850 Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2020 and 2019 are as follows: Year ended December 31 2020 2019 Domestic $ (6,632,593 ) $ (6,975,747 ) Foreign (44,994 ) 53,210 Net Pre-Tax Loss $ (6,677,587 ) $ (6,922,537 ) The income tax provision (benefit) consists of the following: Year ended December 31 2020 2019 Federal: Current $ - $ - Deferred 21.00 % 221,598 (1,361,582 ) State and local: Current - - Deferred 5.14 % 54,186 (332,939 ) 26.14 % 275,784 (1,694,521 ) Change in valuation allowance (275,784 ) 1,694,521 Income tax provision (benefit) $ - $ - The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate are as follows: Year Ended December 31 2020 2019 Tax benefit at federal statutory rate (21.0 )% (21.0 )% State income taxes, net of federal benefit (5.1 )% (5.1 )% Permanent differences (0.7 )% (1.3 )% Change in valuation allowance (4.1 )% 24.5 % Prior year true-up 23.1 % (0.1 )% Expiration of state net operating loss carryforwards 4.5 % 3.1 % Expiration of warrants and options 3.5 % 0.0 % Miscellaneous 0.0 % 0.0 % Effective income tax rate 0.0 % 0.1 % The components of the Company’s deferred income taxes are summarized below: December 31 2020 2019 Deferred Tax Assets: Net operating loss carryforwards $ 42,779,580 $ 41,959,558 Stock-based compensation 428,726 2,215,928 Research and development credit carryovers 2,985,215 2,917,857 Contribution carryovers 10,062 10,062 Intangible assets 94,295 - Accrued liabilities 1,503,190 1,041,286 Gross deferred tax assets 47,801,068 48,144,691 Deferred Tax Liabilities: Intangible assets - (59,616 ) Prepaid expenses (82,839 ) (91,084 ) Other (40,603 ) (40,581 ) Gross deferred tax liabilities (123,442 ) (191,281 ) Valuation allowance (47,677,626 ) (47,953,410 ) Deferred tax asset, net of valuation allowance $ - $ - Change in valuation allowance $ 275,784 $ (1,694,521 ) A valuation allowance against deferred tax assets is required if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets may not be realized. The Company is in the early stages of development and realization of the deferred tax assets is not considered more likely than not. As a result, the Company has recorded a full valuation allowance for the net deferred tax asset. Since inception of the Company on January 17, 2002, the Company has generated federal, state and Australian tax net operating losses of approximately $166 million, $153 million, and $326 thousand. Under the Tax Cuts and Jobs Act, net operating loss incurred after December 31, 2017 may be carried forward indefinitely. The tax loss carry-forwards of the Company may be subject to limitation by Section 382 of the Internal Revenue Code with respect to the amount utilizable each year. This limitation reduces the Company’s ability to utilize net operating loss carry-forwards. Federal net operating losses (“NOL”) totaling $151.4 million expire in various amounts between 2022 and 2037. Federal NOL totaling $14.5 million do not expire. Year Generated Year Expired Amount 2002 2022 $ 5,794,541 2003 2023 1,520,649 2004 2024 3,571,227 2005 2025 5,530,815 2006 2026 7,192,407 2007 2027 10,218,952 2008 2028 7,017,372 2009 2029 9,573,948 2010 2030 10,344,298 2011 2031 11,225,047 2012 2032 11,193,882 2013 2033 10,273,181 2014 2034 9,075,738 2015 2035 17,455,417 2016 2036 19,710,699 2017 2037 11,703,175 2018 N/A 6,255,067 2019 N/A 4,085,063 2020 N/A 4,185,506 Total NOL $ 165,926,984 State NOL totaling $153 million expire in various years between 2021 and 2035. Year Generated Year Expired Amount 2006 2021 $ 7,358,979 2007 2022 10,318,963 2008 2023 7,106,425 2009 2024 9,680,770 2010 2025 10,440,651 2011 2026 11,362,120 2012 2027 11,311,394 2013 2028 10,381,763 2014 2029 9,278,510 2015 2030 18,547,287 2016 2031 20,166,661 2017 2032 12,131,850 2018 2033 6,455,113 2019 2034 4,211,210 2020 2035 4,185,506 Total NOL $ 152,937,202 Australia NOL totaling $326,000 do not expire. Year Generated Year Expired Amount 2017 N/A $ - 2018 N/A 290,490 2019 N/A 35,861 Total NOL $ 326,351 The Company has determined that there are no uncertain tax positions as of December 31, 2020 or 2019. The Company files income tax returns in the U.S. federal jurisdiction and the state of Tennessee. The Company intends to permanently reinvest earnings in its foreign subsidiary. To date, the Company’s operations conducted by its Australian subsidiary consist primarily of research and development activities. As of December 31, 2020, there were no accumulated earnings and profits in the Company’s foreign subsidiary. At current tax rates, no additional Federal income taxes (net of available tax credits) would be payable if such earnings were to be repatriated.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments	11. Commitments Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022. Payments are approximately $7,900 per month. Total expense for operating leases for the year ended December 31, 2020 was $90,821, of which, $60,547 was included within research and development and $30,274 was included within general and administrative expenses on the consolidated statement of operations. Total expense for operating leases for the year ended December 31, 2019 was $102,378, of which, $68,252 was included within research and development and $34,126 was included within general and administrative expenses on the consolidated statement of operations. As of December 31, 2020, the Company had no leases that were classified as a financing lease. As of December 31, 2020, the Company did not have additional operating and financing leases that have not yet commenced.  A summary of the Company’s right-of-use assets and liabilities is as follows: For The Years Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 91,605 $ 89,574 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ 265,550 Weighted Average Remaining Lease Term Operating leases 1.50 Years 2.75 Years Weighted Average Discount Rate Operating leases 8.0 % 8.0 % Future minimum payments under non-cancellable lease as of December 31, 2020 were as follows: Years Amount 2021 92,471 2022 46,687 Total future minimum lease payments 139,158 Less: amount representing imputed interest (9,992 ) Total $ 129,166 12. 401(K) Profit Sharing Plan The Company maintains a retirement plan under Section 401(k) of the Internal Revenue Code, which covers all eligible employees. All employees with U.S. source income are eligible to participate in the plan immediately upon employment. There was no contribution made by the Company in 2020 or 2019.

401(K) Profit Sharing Plan

401(K) Profit Sharing Plan	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
401(K) Profit Sharing Plan	12. 401(K) Profit Sharing Plan The Company maintains a retirement plan under Section 401(k) of the Internal Revenue Code, which covers all eligible employees. All employees with U.S. source income are eligible to participate in the plan immediately upon employment. There was no contribution made by the Company in 2020 or 2019.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Litigation	13. Litigation Culpepper Travel Expenses and Related Collection Efforts On December 27, 2016, the then-Board of Directors (the “then-Board”) unanimously voted to terminate then-interim Chief Executive Officer, then-Chief Operating Officer, and former Chief Financial Officer, Peter Culpepper (“Culpepper”), effective immediately, from all positions he held with the Company and each of its subsidiaries, “for cause,” in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”), based on the results of the investigation conducted by the Audit Committee of the then-Board regarding improper expense reimbursements to Culpepper. The Company took the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Stipulated Settlement Agreement and Mutual Release in the Kleba Derivative Lawsuit Settlement (the “Derivative Lawsuit Settlement”) such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,104,543 as of December 31, 2020 and December 31, 2019, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount. Culpepper disputed that he was terminated “for cause” under the Culpepper Employment Agreement. On June 28, 2017, pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating Culpepper’s claim against the Company for severance and the Company’s claims against Culpepper for improper expense reimbursements and amounts Culpepper owed the Company under the Derivative Lawsuit Settlement. On September 12, 2018, the arbitrator issued his final award in favor of the Company. On October 4, 2018, the Company filed a petition with the Chancery Court for Davidson County, Tennessee to confirm the arbitration award. On January 23, 2019, the Chancery Court entered an order confirming the arbitrator’s award. On February 20, 2019, Culpepper filed a motion to alter or amend the Chancery Court’s judgment. On March 22, 2019, the Chancery Court upheld the arbitration award in favor of the Company. On April 16, 2019, Culpepper filed a Notice of Appeal with the Tennessee Court of Appeals regarding the Chancery Court’s judgment. The Company and Culpepper submitted their respective court of appeal briefs on November 12, 2019 and December 3, 2019, respectively. Oral arguments were held on January 7, 2020. On April 14, 2020, the Court of Appeals affirmed the Chancery Court’s judgment and awarded court costs to the Company. On June 16, 2020, Culpepper filed an application to the Supreme Court of Tennessee for permission to appeal the Court of Appeals’ final decision. On June 30, 2020, the Company filed an answer to the Supreme Court in opposition to Culpepper’s application for permission to appeal. On August 5, 2020, the Supreme Court of Tennessee denied Culpepper’s application. On November 3, 2020, Culpepper filed a petition for writ of certiorari to the Supreme Court of the United States “SCOTUS”). The petition for writ of certiorari was denied by the Supreme Court on January 11, 2021. There are no further avenues for appeal for Culpepper.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Convertible Notes Payable Subsequent to December 31, 2020, the Company entered into a 2020 Note with a non-related party accredited investor in the aggregate principal amount of $1,200,000 in connection with 2 nd Exercise of Warrants In addition, holders of 4,500,000 warrants to purchase the common stock of the Company at $0.0533 per share, have exercised these warrants. The Company has received proceeds in the aggregate amount of $239,850.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the collectability of receivables, the recoverability and useful lives of long-lived assets, stock-based compensation, accrued liabilities and the valuation allowance related to the Company’s deferred tax assets.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of December 31, 2020 and 2019, the Company’s cash equivalent consists of Treasury bills.
Cash Concentrations	Cash Concentrations Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits of $250,000, although the Company seeks to minimize this through treasury management. The Company has never experienced any losses related to these balances although no assurance can be provided that it will not experience any losses in the future.
Equipment and Furnishings, Net	Equipment and Furnishings, net Equipment and furnishings are stated at cost less accumulated depreciation. Depreciation of equipment is provided for using the straight-line method over the estimated useful lives of the assets. Computers, leasehold improvements and office equipment are being depreciated over five years; furniture and fixtures are being depreciated over ten years. Maintenance and repairs are charged to operations as incurred. The Company capitalizes cost attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.
Long-lived Assets	Long-Lived Assets The Company reviews the carrying values of its long-lived assets for possible impairment whenever an event or change in circumstances indicates that the carrying amount of the assets may not be recoverable. Any long-lived assets held for disposal are reported at the lower of their carrying amounts or fair value less cost to sell. Management has determined there to be no impairment during the years ended December 31, 2020 and 2019.
Patent Costs, Net	Patent Costs, net Internal patent costs are expensed in the period incurred. Patents purchased are capitalized and amortized over the remaining estimated useful life of the patent. The patents are fully amortized. Annual amortization of the patents was $228,000 in 2020.
Related Party Receivables	Related Party Receivables Management estimates the reserve for uncollectibility based on existing economic conditions, the financial conditions of the current and former employees, and the amount and age of past due receivables. Receivables are considered past due if full payment is not received by the contractual due date. Past due amounts are generally written off against the reserve for uncollectibility only after all collection attempts have been exhausted. See Note 7 – Short-term Receivables.
Research and Development	Research and Development Research and development costs are charged to expense when incurred. An allocation of payroll expenses to research and development is made based on a percentage estimate of time spent. The research and development costs include the following: payroll, consulting and contract labor, lab supplies and pharmaceutical preparations, insurance, rent and utilities, and depreciation and amortization.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued a new standard related to leases to increase transparency and comparability among organizations by requiring the recognition of operating lease right-of-use (“ROU”) assets and lease liabilities on the balance sheet (“ASC 842”) with amendments issued in 2018. Most prominent among the changes in the standard is the recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The Company is also required to recognize and measure new leases at the adoption date and recognize a cumulative-effect adjustment in the period of adoption using a modified retrospective approach, with certain practical expedients available. The Company adopted ASC 842 effective January 1, 2019 and elected to apply the available practical expedients. The standard had an impact on the Company’s consolidated balance sheets but did not have a material impact on the Company’s consolidated statements of operations or cash flows upon adoption. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method in accordance with Accounting Standards Codification (“ASC”) 740 “Income Taxes”. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established if it is more likely than not that all, or some portion, of deferred income tax assets will not be realized. The Company has recorded a full valuation allowance to reduce its net deferred income tax assets to zero. In the event the Company were to determine that it would be able to realize some or all its deferred income tax assets in the future, an adjustment to the deferred income tax asset would increase income in the period such determination was made. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained upon an examination. Any recognized income tax positions would be measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement would be reflected in the period in which the change in judgment occurs. The Company would recognize any corresponding interest and penalties associated with its income tax positions in income tax expense. There were no income taxes, interest or penalties incurred in 2020 or 2019.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2020 2019 Warrants 87,264,164 126,109,532 Options 4,800,000 3,000,000 Convertible preferred stock 65,663 65,663 Total potentially dilutive shares 92,129,827 129,175,195 The potential dilutive effect of the conversion of the Company’s convertible notes payable has been excluded from this table since the Company’s Series D Preferred Stock has yet to be designated by the Board.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The Company determines the estimated fair value of amounts presented in these consolidated financial statements using available market information and appropriate methodologies. However, considerable judgment is required in interpreting market data to develop the estimates of fair value. The estimates presented in the financial statements are not necessarily indicative of the amounts that could be realized in a current exchange between buyer and seller. The use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts. These fair value estimates were based upon pertinent information available as of December 31, 2020 and 2019. The carrying amounts of the Company’s financial assets and liabilities, such as cash and cash equivalents, receivables, other current assets, accounts payable, and accrued expenses approximate fair values due to the short-term nature of these instruments. The carrying amounts of our credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 Inputs use directly or indirectly observable inputs. These inputs include quoted prices for similar assets and liabilities in active markets as well as other inputs such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 Inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset or liability. In instances where inputs used to measure fair value fall into different levels in the above fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The Company’s assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. Both observable and unobservable inputs may be used to determine the fair value of positions that are classified within the Level 3 category. As a result, the unrealized gains and losses for assets within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in historical company data) inputs. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.
Foreign Currency Translation	Foreign Currency Translation The Company’s reporting currency is the United States Dollar. The functional currencies of the Company’s operating subsidiaries are their local currencies (United States Dollar and Australian Dollar). Australian Dollar denominated assets and liabilities are translated into the United States Dollar at the balance sheet date ($10,552 and $332,446 at December 31, 2020 and $61,380 and $308,915 at December 31, 2019, respectively), and expense and other income accounts are translated at a weighted average exchange rate for the years then ended ($44,994 and $53,210 for the years ended December 31, 2020 and 2019, respectively). Equity is translated at historical rates and the resulting foreign currency translation adjustments are included as a component of accumulated other comprehensive loss (“AOCL”), which is a separate component of shareholders’ deficit. Therefore, the U.S. dollar value of the non-equity translated items in the Company’s consolidated financial statements will fluctuate from period to period, depending on the changing value of the U.S. dollar versus these currencies. The Company engages in foreign currency denomination transactions with its Australian subsidiary. At the date that the transaction is recognized, each asset, liability, revenue, expense, gain or loss arising from the transaction is measured and recorded in the functional currency of the recording entity using the exchange rate in effect at that date. At each balance sheet date, recorded monetary balances denominated in a currency other than the functional currency are adjusted using the exchange rate at the balance sheet date, with gains or losses recorded in other income or other expense.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and then is recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company computes the fair value of equity-classified warrants and options granted using the Black-Scholes option pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of the Company’s common stock which is determined by reviewing its historical public market closing prices.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes. Income Taxes In January 2020, the FASB issued ASU 2020-01, “Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815).” ASU 2020-01 states any equity security transitioning from the alternative method of accounting under Topic 321 to the equity method, or vice versa, due to an observable transaction will be remeasured immediately before the transition. In addition, the ASU clarifies the accounting for certain non-derivative forward contracts or purchased call options to acquire equity securities stating such instruments will be measured using the fair value principles of Topic 321 before settlement or exercise. The ASU is effective for fiscal years beginning after December 15, 2020, and will be applied on a prospective basis. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s consolidated financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its consolidated financial statements and related disclosures. In August 2020, FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). Under ASU 2020-06, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new guidance also requires the if-converted method to be applied for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. Adoption of the standard requires using either a modified retrospective or a full retrospective approach. The Company is currently evaluating the effect of the adoption of ASU 2020-06 will have on its consolidated financial statements and related disclosures. In October 2020, the FASB issued ASU 2020-10 “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance is effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company is currently assessing the impact that this pronouncement will have on its consolidated financial statements.
Recent Adopted Accounting Pronouncements	Recent Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 significantly changes the impairment model for most financial assets and certain other instruments. ASU 2016-13 will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets, which will generally result in earlier recognition of allowances for credit losses on loans and other financial instruments. ASU 2016-13 is effective for the Company’s fiscal year beginning December 1, 2019 and subsequent interim periods. The Company is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated financial statements. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments —Credit Losses, ASU 2019-05, Financial Instruments —Credit Losses (Topic 326) Targeted Transition Relief, ASU 2016-13, the FASB issued ASU 2019-10 Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11 Codification Improvements to Topic 326, Financial Instruments—Credit Losses. These ASUs do not change the core principle of the guidance in ASU 2016-13. Instead, these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard. These ASUs will have the same effective date and transition requirements as ASU 2016-13. The Company adopted ASU 2016-13 on January 1, 2020 and it did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company adopted ASU effective January 1, 2020 and it did not have a material impact on the consolidated financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: December 31, 2020 2019 Warrants 87,264,164 126,109,532 Options 4,800,000 3,000,000 Convertible preferred stock 65,663 65,663 Total potentially dilutive shares 92,129,827 129,175,195

Short-Term Receivables (Tables)

Short-Term Receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Summary of Receivables	The following table summarizes the receivables at December 31, 2020 and 2019: December 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia tax credit $ 3,930 $ - $ - $ 3,930 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 3,930 $ - $ - $ 3,930 December 31, 2019 Legal Fees Legal Fees Settlement Total Provectus Australia tax credit $ 55,058 $ - $ - $ 55,058 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 55,058 $ - $ - $ 55,058

Stock Incentive Plan and Warr_2

Stock Incentive Plan and Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Stock Options Granted Valued Using Black Scholes Model	Stock Options granted during the year ended December 31, 2020 were valued using the Black Scholes Model, with the following assumptions used: For the Years Ended December 31, 2020 2019 Expected terms (years) 2.50 - Expected volatility 93 % - Risk-free interest rate 0.23 % - Expected dividend 0.00 % -
Summary of Option Activity	The following table summarizes option activity during the year ended December 31, 2020 and 2019: Weighted Average Options Exercise Price Outstanding and exercisable at January 1, 2019 3,200,000 $ 0.89 Granted - - Exercised - - Forfeited (200,000 ) 0.88 Outstanding and exercisable at December 31, 2019 3,000,000 $ 0.88 Granted 2,525,000 .20 Exercised - - Forfeited (725,000 ) 0.88 Outstanding and exercisable at December 31, 2020 4,800,000 $ 0.46
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2020. Number Outstanding Weighted Average Number Exercisable Exercise Price at December 31, 2020 Life at December 31, 2020 $ 0.12 2,425,000 4.90 2,425,000 $ 0.29 100,000 4.90 100,000 $ 0.67 200,000 2.60 200,000 $ 0.75 950,000 3.11 950,000 $ 0.84 150,000 1.50 150,000 $ 0.88 150,000 3.60 150,000 $ 0.93 575,000 0.76 575,000 $ 0.99 50,000 0.50 50,000 $ 1.04 200,000 0.50 200,000 4,800,000 3.58 4,800,000
Schedule of Assumptions of Warrants	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following assumptions: For the Years Ended December 31, 2020 2019 Contractual terms (years) 3.00 3.00-5.00 Expected volatility 93%-95 % 129%-131 % Risk-free interest rate .011%-0.18 % 1.82%-2.33 % Expected dividend 0.00 % 0.00 %
Summary of Warrant Activity	The following table summarizes warrant activity during the year ended December 31, 2020 and 2019: Weighted Average Warrants Exercise Price Outstanding and exercisable at January 1, 2019 136,824,138 $ 0.27 Granted 425,000 0.94 Exercised (5,045,857 ) 0.05 Forfeited (6,093,749 ) 1.20 Outstanding and exercisable at December 31, 2019 126,109,532 $ 0.29 Granted 62,500 0.29 Exercised (7,855,062 ) 0.05 Forfeited (31,052,806 ) 1.06 Outstanding and exercisable at December 31, 2020 87,264,164 $ 0.02
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding at December 31, 2020. Number Outstanding Weighted Average Number Exercisable Intrinsic Value at December 31, Remaining Contractual at December 31, at December 31, Exercise Price 2020 Life 2020 2020 $ 0.05 86,776,664 0.66 86,776,664 $ 407,850 $ 0.29 100,000 2.30 100,000 $ - $ 1.00 18,000 3.39 18,000 $ - $ 1.12 366,000 3.38 366,000 $ - $ 2.00 3,500 3.38 3,500 $ - 87,264,164 2.62 87,264,164 $ 407,850

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Domestic and Foreign Loss Before Income Taxes	The domestic and foreign components of loss before income taxes from operations for the years ended December 31, 2020 and 2019 are as follows: Year ended December 31 2020 2019 Domestic $ (6,632,593 ) $ (6,975,747 ) Foreign (44,994 ) 53,210 Net Pre-Tax Loss $ (6,677,587 ) $ (6,922,537 )
Summary of Income Tax Provision (Benefit)	The income tax provision (benefit) consists of the following: Year ended December 31 2020 2019 Federal: Current $ - $ - Deferred 21.00 % 221,598 (1,361,582 ) State and local: Current - - Deferred 5.14 % 54,186 (332,939 ) 26.14 % 275,784 (1,694,521 ) Change in valuation allowance (275,784 ) 1,694,521 Income tax provision (benefit) $ - $ -
Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate	The reconciliations between the statutory federal income tax rate and the Company’s effective tax rate are as follows: Year Ended December 31 2020 2019 Tax benefit at federal statutory rate (21.0 )% (21.0 )% State income taxes, net of federal benefit (5.1 )% (5.1 )% Permanent differences (0.7 )% (1.3 )% Change in valuation allowance (4.1 )% 24.5 % Prior year true-up 23.1 % (0.1 )% Expiration of state net operating loss carryforwards 4.5 % 3.1 % Expiration of warrants and options 3.5 % 0.0 % Miscellaneous 0.0 % 0.0 % Effective income tax rate 0.0 % 0.1 %
Schedule of Components of Deferred Income Taxes	The components of the Company’s deferred income taxes are summarized below: December 31 2020 2019 Deferred Tax Assets: Net operating loss carryforwards $ 42,779,580 $ 41,959,558 Stock-based compensation 428,726 2,215,928 Research and development credit carryovers 2,985,215 2,917,857 Contribution carryovers 10,062 10,062 Intangible assets 94,295 - Accrued liabilities 1,503,190 1,041,286 Gross deferred tax assets 47,801,068 48,144,691 Deferred Tax Liabilities: Intangible assets - (59,616 ) Prepaid expenses (82,839 ) (91,084 ) Other (40,603 ) (40,581 ) Gross deferred tax liabilities (123,442 ) (191,281 ) Valuation allowance (47,677,626 ) (47,953,410 ) Deferred tax asset, net of valuation allowance $ - $ - Change in valuation allowance $ 275,784 $ (1,694,521 )
Schedule of Net Operating Loss	Year Generated Year Expired Amount 2002 2022 $ 5,794,541 2003 2023 1,520,649 2004 2024 3,571,227 2005 2025 5,530,815 2006 2026 7,192,407 2007 2027 10,218,952 2008 2028 7,017,372 2009 2029 9,573,948 2010 2030 10,344,298 2011 2031 11,225,047 2012 2032 11,193,882 2013 2033 10,273,181 2014 2034 9,075,738 2015 2035 17,455,417 2016 2036 19,710,699 2017 2037 11,703,175 2018 N/A 6,255,067 2019 N/A 4,085,063 2020 N/A 4,185,506 Total NOL $ 165,926,984 Year Generated Year Expired Amount 2006 2021 $ 7,358,979 2007 2022 10,318,963 2008 2023 7,106,425 2009 2024 9,680,770 2010 2025 10,440,651 2011 2026 11,362,120 2012 2027 11,311,394 2013 2028 10,381,763 2014 2029 9,278,510 2015 2030 18,547,287 2016 2031 20,166,661 2017 2032 12,131,850 2018 2033 6,455,113 2019 2034 4,211,210 2020 2035 4,185,506 Total NOL $ 152,937,202 Year Generated Year Expired Amount 2017 N/A $ - 2018 N/A 290,490 2019 N/A 35,861 Total NOL $ 326,351

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: For The Years Ended December 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 91,605 $ 89,574 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ 265,550 Weighted Average Remaining Lease Term Operating leases 1.50 Years 2.75 Years Weighted Average Discount Rate Operating leases 8.0 % 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under non-cancellable lease as of December 31, 2020 were as follows: Years Amount 2021 92,471 2022 46,687 Total future minimum lease payments 139,158 Less: amount representing imputed interest (9,992 ) Total $ 129,166

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	2 Months Ended	12 Months Ended
	Mar. 02, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents		$ 97,231	$ 590,706
Warrants exercise price		$ 0.053	$ 0.053
Proceeds from exercise of warrants		$ 418,676	$ 268,943
Subsequent Event [Member]
Loans received in connection with financing	$ 1,200,000
Warrant to purchase common stock	4,500,000
Warrants exercise price	$ 0.0533
Proceeds from exercise of warrants	$ 239,850

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Summary Of Significant Accounting Policy [Line Items]
Maturity of highly liquid investments	Three months or less
Amount of insurance coverage	$ 250,000
Impairment of long lived assets
Recognized income tax positions measured	50.00%
Income taxes, interest or penalties incurred
Foreign currency translation adjustment of expense and other income at weighted average exchange rate	$ 44,994	53,210
Computer Equipment [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	5 years
Leasehold Improvements [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	5 years
Office Equipment [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	5 years
Furniture and Fixtures [Member]
Summary Of Significant Accounting Policy [Line Items]
Estimated useful lives of the assets	10 years
Patents [Member]
Summary Of Significant Accounting Policy [Line Items]
Amortization of patents, 2020	$ 228,000
USD [Member]
Summary Of Significant Accounting Policy [Line Items]
Foreign currency translation adjustments of assets in USD	10,552	61,380
Foreign currency translation adjustments of liabilities in USD	$ 332,446	$ 308,915

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	92,129,827	129,175,195
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	65,663	65,663
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	87,264,164	126,109,532
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	4,800,000	3,000,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 20, 2019	Feb. 28, 2018	Mar. 23, 2017
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Borrowed outstanding convertible notes payable	$ 16,622,000	$ 500,000
2017 [Member] | Non-Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount		6,335,000
Borrowed outstanding convertible notes payable	13,397,000	13,397,000
2017 [Member] | Dr. Scott's Kleba Settlement Agreement [Member]
Related Party Transaction [Line Items]
Debt principal amount				$ 250,000
2017 [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	50,000
Borrowed outstanding convertible notes payable	6,670,000	6,670,000
2020 Notes [Member]
Related Party Transaction [Line Items]
Debt principal amount		100,000
Borrowed outstanding convertible notes payable		100,000
2020 Notes [Member] | Non-Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	3,125,000
Borrowed outstanding convertible notes payable	3,225,000
2020 Notes [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	100,000
Borrowed outstanding convertible notes payable	100,000
2017 Financing [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount					$ 10,000,000
2017 Financing [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount					$ 20,000,000
2017 Financing [Member]
Related Party Transaction [Line Items]
Proceeds from loans	$ 20,067,000
Interest rate	8.00%
2017 Financing [Member] | First And Final Tranche [Member]
Related Party Transaction [Line Items]
Financing arrangement amount			$ 20,000,000
2017 Financing [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 0.2862
2017 Financing [Member] | Series D Preferred Stock [Member] | Final Tranche [Member]
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 0.2862
2020 Financing [Member]
Related Party Transaction [Line Items]
Proceeds from loans	$ 3,325,000
Interest rate	8.00%
2020 Financing [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Preferred stock, par or stated value per share	$ 2.8620
2020 Financing [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount		$ 20,000,000
2017 and 2020 Financings [Member]
Related Party Transaction [Line Items]
Interest rate	8.00%

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Apr. 20, 2020	Dec. 31, 2020	Dec. 31, 2019
Note payable		$ 212,790	$ 228,424
Paycheck Protection Program [Member] | The CARES Act [Member]
Proceeds from loans	$ 62,500
Debt instrument description	The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower's average monthly payroll expenses.
Interest rate	1.00%
Debt instrument term	2 years

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Accrued director fees	$ 1,175,589	$ 792,524
Directors fees	383,065	385,000
Mr Bruce Horowitz [Member]
Consulting fees	254,400	277,200
Accrued director fees	$ 75,000	$ 75,000

Short-Term Receivables (Details

Short-Term Receivables (Details Narrative)	12 Months Ended
	Dec. 31, 2019USD ($)
Receivables [Abstract]
Offset against accrued payroll and other payables	$ 535,361

Short-Term Receivables - Summar

Short-Term Receivables - Summary of Receivables (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Tax Credit	$ 3,930	$ 55,058
Gross receivable	2,104,543	2,104,543
Reserve for uncollectibility	(2,104,543)	(2,104,543)
Net receivable	3,930	55,058
Legal Fees [Member]
Tax Credit
Gross receivable	455,500	455,500
Reserve for uncollectibility	(455,500)	(455,500)
Net receivable
Settlement [Member]
Tax Credit
Gross receivable	1,649,043	1,649,043
Reserve for uncollectibility	(1,649,043)	(1,649,043)
Net receivable
Provectus Australia [Member]
Tax Credit	3,930	55,058
Gross receivable
Reserve for uncollectibility
Net receivable	$ 3,930	$ 55,058

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Aug. 25, 2016
Class of Stock [Line Items]
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Number of restricted common stock issued	1,062,500	229,090
Number of restricted common stock issued, value	$ 69,088	$ 11,538
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	240,000	240,000
Preferred stock, par value			$ 0.001
Preferred stock, dividend percentage	8.00%
Undesignated Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	24,760,000

Stock Incentive Plan and Warr_3

Stock Incentive Plan and Warrants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of common stock issued	2,525,000
Options, outstanding, intrinsic value	$ 0
Options, exercisable, intrinsic value	$ 0
Warrants exercise price	$ 0.053	$ 0.053
Proceeds from warrant exercise	$ 418,676	$ 268,943
Number of shares of common stock issued	7,855,062	5,045,857
Warrant [Member]
Warrants to purchase shares of common stock	7,855,062	5,045,857
Three Year Immediately Vested Warrants [Member]
Warrants to purchase shares of common stock	62,500
Warrants exercise price	$ 0.2862
Aggregate purchase of common stock, shares	62,500
Aggregate fair value of warrants	$ 1,372
Officer or Director [Member] | Five-Year Immediately Vested [Member]
Number of available for issuance	2,425,000
Options vesting period	5 years
Vested stock options to purchase shares of common stock	2,425,000
Vested stock options exercise price	$ 0.12
Stock options aggregate grant date fair value	$ 62,880
Director [Member] | Five-Year Immediately Vested [Member]
Number of available for issuance	100,000
Options vesting period	5 years
Vested stock options to purchase shares of common stock	100,000
Vested stock options exercise price	$ 0.2862
Stock options aggregate grant date fair value	$ 1,414
2017 Equity Compensation Plan [Member]
Number of available for issuance	15,312,500
2017 Equity Compensation Plan [Member] | Maximum [Member]
Number of common stock issued	20,000,000
Stock options period	10 years

Stock Incentive Plan and Warr_4

Stock Incentive Plan and Warrants - Schedule of Stock Options Granted Valued Using Black Scholes Model (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Expected terms (years)	2 years 6 months
Expected volatility	93.00%
Risk free interest rate	0.23%
Expected dividends	0.00%

Stock Incentive Plan and Warr_5

Stock Incentive Plan and Warrants - Summary of Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Number of Options Outstanding and exercisable, beginning balance	3,000,000	3,200,000
Number of Options, Granted	2,525,000
Number of Options, Exercised
Number of Options, Forfeited	(725,000)	(200,000)
Number of Options Outstanding and exercisable, ending balance	4,800,000	3,000,000
Weighted Average Exercise Price Outstanding and exercisable, beginning balance	$ 0.88	$ 0.89
Weighted Average Exercise Price, Granted	.20
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited	0.88	0.88
Weighted Average Exercise Price Outstanding and exercisable, ending balance	$ 0.46	$ 0.88

Stock Incentive Plan and Warr_6

Stock Incentive Plan and Warrants - Summary of Stock Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Number Outstanding	4,800,000
Weighted Average Remaining Contractual Life	3 years 6 months 29 days
Number Exercisable	4,800,000
Range One [Member]
Exercise price | $ / shares	$ 0.12
Number Outstanding	2,425,000
Weighted Average Remaining Contractual Life	4 years 10 months 25 days
Number Exercisable	2,425,000
Range Two [Member]
Exercise price | $ / shares	$ 0.29
Number Outstanding	100,000
Weighted Average Remaining Contractual Life	4 years 10 months 25 days
Number Exercisable	100,000
Range Three [Member]
Exercise price | $ / shares	$ 0.67
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	2 years 7 months 6 days
Number Exercisable	200,000
Range Four [Member]
Exercise price | $ / shares	$ 0.75
Number Outstanding	950,000
Weighted Average Remaining Contractual Life	3 years 1 month 9 days
Number Exercisable	950,000
Range Five [Member]
Exercise price | $ / shares	$ 0.84
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	1 year 6 months
Number Exercisable	150,000
Range Six [Member]
Exercise price | $ / shares	$ 0.88
Number Outstanding	150,000
Weighted Average Remaining Contractual Life	3 years 7 months 6 days
Number Exercisable	150,000
Range Seven [Member]
Exercise price | $ / shares	$ 0.93
Number Outstanding	575,000
Weighted Average Remaining Contractual Life	9 months 3 days
Number Exercisable	575,000
Range Eight [Member]
Exercise price | $ / shares	$ 0.99
Number Outstanding	50,000
Weighted Average Remaining Contractual Life	6 months
Number Exercisable	50,000
Range Nine [Member]
Exercise price | $ / shares	$ 1.04
Number Outstanding	200,000
Weighted Average Remaining Contractual Life	6 months
Number Exercisable	200,000

Stock Incentive Plan and Warr_7

Stock Incentive Plan and Warrants - Schedule of Assumptions of Warrants (Details)	Dec. 31, 2020	Dec. 31, 2019
Warrants, contracual terms (years)	3 years
Expected Dividends [Member]
Warrants outstanding, measurement input	0	0
Minimum [Member]
Warrants, contracual terms (years)		3 years
Minimum [Member] | Expected Volatility [Member]
Warrants outstanding, measurement input	93	129
Minimum [Member] | Risk Free Interest Rate [Member]
Warrants outstanding, measurement input	0.011	1.82
Maximum [Member]
Warrants, contracual terms (years)		5 years
Maximum [Member] | Expected Volatility [Member]
Warrants outstanding, measurement input	95	131
Maximum [Member] | Risk Free Interest Rate [Member]
Warrants outstanding, measurement input	0.18	2.23

Stock Incentive Plan and Warr_8

Stock Incentive Plan and Warrants - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Warrants Outstanding and exercisable, beginning balance	126,109,532	136,824,138
Warrants, Granted	62,500	425,000
Warrants, Exercised	(7,855,062)	(5,045,857)
Warrants, Forfeited	(31,052,806)	(6,093,749)
Warrants Outstanding and exercisable, ending balance	87,264,164	126,109,532
Weighted Average Exercise Price Outstanding and exercisable, beginning balance	$ 0.29	$ 0.27
Weighted Average Exercise Price, Granted	0.29	0.94
Weighted Average Exercise Price, Exercised	0.05	0.05
Weighted Average Exercise Price, Forfeited	1.06	1.20
Weighted Average Exercise Price Outstanding and exercisable, ending balance	$ 0.02	$ 0.29

Stock Incentive Plan and Warr_9

Stock Incentive Plan and Warrants - Summary of Warrants Outstanding (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Weighted Average Exercise price
Number Outstanding	4,800,000
Number Exercisable	4,800,000
Range One [Member]
Number Outstanding	2,425,000
Number Exercisable	2,425,000
Range Two [Member]
Number Outstanding	100,000
Number Exercisable	100,000
Range Three [Member]
Number Outstanding	200,000
Number Exercisable	200,000
Range Four [Member]
Number Outstanding	950,000
Number Exercisable	950,000
Range Five [Member]
Number Outstanding	150,000
Number Exercisable	150,000
Range Six [Member]
Number Outstanding	150,000
Number Exercisable	150,000
Warrant [Member] | Range One [Member]
Weighted Average Exercise price	$ 0.05
Number Outstanding	86,776,664
Weighted Average Remaining Contractual Life	7 months 28 days
Number Exercisable	86,776,664
Intrinsic Value	$ 407,850
Warrant [Member] | Range Two [Member]
Weighted Average Exercise price	$ 0.29
Number Outstanding	100,000
Weighted Average Remaining Contractual Life	2 years 3 months 19 days
Number Exercisable	100,000
Intrinsic Value
Warrant [Member] | Range Three [Member]
Weighted Average Exercise price	$ 1
Number Outstanding	18,000
Weighted Average Remaining Contractual Life	3 years 4 months 20 days
Number Exercisable	18,000
Intrinsic Value
Warrant [Member] | Range Four [Member]
Weighted Average Exercise price	$ 1.12
Number Outstanding	366,000
Weighted Average Remaining Contractual Life	3 years 4 months 17 days
Number Exercisable	366,000
Intrinsic Value
Warrant [Member] | Range Five [Member]
Weighted Average Exercise price	$ 2
Number Outstanding	3,500
Weighted Average Remaining Contractual Life	3 years 4 months 17 days
Number Exercisable	3,500
Intrinsic Value
Warrant [Member] | Range Six [Member]
Number Outstanding	87,264,164
Weighted Average Remaining Contractual Life	2 years 7 months 13 days
Number Exercisable	87,264,164
Intrinsic Value	$ 407,850

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Line Items]
Tax net operating losses	$ 14,500,000
Uncertain tax positions
Federal [Member]
Income Taxes [Line Items]
Tax net operating losses	166,000,000
Federal [Member] | Between 2022 and 2037 [Member]
Income Taxes [Line Items]
Tax net operating losses	151,400,000
State [Member]
Income Taxes [Line Items]
Tax net operating losses	153,000,000
State [Member] | Between 2021 and 2035 [Member]
Income Taxes [Line Items]
Tax net operating losses	153,000,000
Australian [Member]
Income Taxes [Line Items]
Tax net operating losses	$ 326,000

Income Taxes - Schedule of Dome

Income Taxes - Schedule of Domestic and Foreign Loss Before Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Domestic	$ (632,593)	$ (6,975,747)
Foreign	(44,994)	53,210
Net Pre-Tax Loss	$ (677,587)	$ (6,922,537)

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal: Current
Federal: Deferred	$ 221,598	$ (1,361,582)
Federal: Deferred tax rate	21.00%	21.00%
State and local: Current
State and local: Deferred	$ 54,186	$ (332,939)
State and local: Deferred tax rate	5.14%	5.14%
Effective deferred tax rate	26.14%	26.14%
Current income tax expense (benefit)	$ 275,784	$ (1,694,521)
Change in valuation allowance	(275,784)	1,694,521
Income tax provision (benefit)

Income Taxes - Schedule of Stat

Income Taxes - Schedule of Statutory Federal Income Tax Rate and Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax benefit at federal statutory rate	(21.00%)	(21.00%)
State income taxes, net of federal benefit	(5.14%)	(5.14%)
Permanent differences	(0.70%)	(1.30%)
Change in valuation allowance	(4.10%)	24.50%
Prior year true-up	23.10%	(0.10%)
Expiration of state net operating loss carry forwards	4.50%	3.10%
Expiration of warrants and options	3.50%	0.00%
Miscellaneous	0.00%	0.00%
Effective income tax rate	0.00%	0.10%

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 42,779,580	$ 41,959,558
Stock-based compensation	428,726	2,215,928
Research and development credit carryovers	2,985,215	2,917,857
Contribution carryovers	10,062	10,062
Intangible assets	94,295
Accrued liabilities	1,503,190	1,041,286
Gross deferred tax assets	47,801,068	48,144,691
Intangible assets		(59,616)
Prepaid expenses	(82,839)	(91,084)
Other	(40,603)	(40,581)
Gross deferred tax liabilities	(123,442)	(191,281)
Valuation allowance	(47,677,626)	(47,953,410)
Deferred tax asset, net of valuation allowance
Change in valuation allowance	$ 275,784	$ (1,694,521)

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Operating Loss (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Income Taxes [Line Items]
Amount	$ 14,500,000
Federal [Member]
Income Taxes [Line Items]
Amount	$ 166,000,000
Federal [Member] | 2002 [Member]
Income Taxes [Line Items]
Year Expired	2022
Amount	$ 5,794,541
Federal [Member] | 2003 [Member]
Income Taxes [Line Items]
Year Expired	2023
Amount	$ 1,520,649
Federal [Member] | 2004 [Member]
Income Taxes [Line Items]
Year Expired	2024
Amount	$ 3,571,227
Federal [Member] | 2005 [Member]
Income Taxes [Line Items]
Year Expired	2025
Amount	$ 5,530,815
Federal [Member] | 2006 [Member]
Income Taxes [Line Items]
Year Expired	2026
Amount	$ 7,192,407
Federal [Member] | 2007 [Member]
Income Taxes [Line Items]
Year Expired	2027
Amount	$ 10,218,952
Federal [Member] | 2008 [Member]
Income Taxes [Line Items]
Year Expired	2028
Amount	$ 7,017,372
Federal [Member] | 2009 [Member]
Income Taxes [Line Items]
Year Expired	2029
Amount	$ 9,573,948
Federal [Member] | 2010 [Member]
Income Taxes [Line Items]
Year Expired	2030
Amount	$ 10,344,298
Federal [Member] | 2011 [Member]
Income Taxes [Line Items]
Year Expired	2031
Amount	$ 11,225,047
Federal [Member] | 2012 [Member]
Income Taxes [Line Items]
Year Expired	2032
Amount	$ 11,193,882
Federal [Member] | 2013 [Member]
Income Taxes [Line Items]
Year Expired	2033
Amount	$ 10,273,181
Federal [Member] | 2014 [Member]
Income Taxes [Line Items]
Year Expired	2034
Amount	$ 9,075,738
Federal [Member] | 2015 [Member]
Income Taxes [Line Items]
Year Expired	2035
Amount	$ 17,455,417
Federal [Member] | 2016 [Member]
Income Taxes [Line Items]
Year Expired	2036
Amount	$ 19,710,699
Federal [Member] | 2017 [Member]
Income Taxes [Line Items]
Year Expired	2037
Amount	$ 11,703,175
Federal [Member] | 2018 [Member]
Income Taxes [Line Items]
Year Expired	None
Amount	$ 6,255,067
Federal [Member] | 2019 [Member]
Income Taxes [Line Items]
Year Expired	None
Amount	$ 4,085,063
Federal [Member] | 2020 [Member]
Income Taxes [Line Items]
Year Expired	None
Amount	$ 4,185,506
State [Member]
Income Taxes [Line Items]
Amount	$ 153,000,000
State [Member] | 2006 [Member]
Income Taxes [Line Items]
Year Expired	2021
Amount	$ 7,358,979
State [Member] | 2007 [Member]
Income Taxes [Line Items]
Year Expired	2022
Amount	$ 10,318,963
State [Member] | 2008 [Member]
Income Taxes [Line Items]
Year Expired	2023
Amount	$ 7,106,425
State [Member] | 2009 [Member]
Income Taxes [Line Items]
Year Expired	2024
Amount	$ 9,680,770
State [Member] | 2010 [Member]
Income Taxes [Line Items]
Year Expired	2025
Amount	$ 10,440,651
State [Member] | 2011 [Member]
Income Taxes [Line Items]
Year Expired	2026
Amount	$ 11,362,120
State [Member] | 2012 [Member]
Income Taxes [Line Items]
Year Expired	2027
Amount	$ 11,311,394
State [Member] | 2013 [Member]
Income Taxes [Line Items]
Year Expired	2028
Amount	$ 10,381,763
State [Member] | 2014 [Member]
Income Taxes [Line Items]
Year Expired	2029
Amount	$ 9,278,510
State [Member] | 2015 [Member]
Income Taxes [Line Items]
Year Expired	2030
Amount	$ 18,547,287
State [Member] | 2016 [Member]
Income Taxes [Line Items]
Year Expired	2031
Amount	$ 20,166,661
State [Member] | 2017 [Member]
Income Taxes [Line Items]
Year Expired	2032
Amount	$ 12,131,850
State [Member] | 2018 [Member]
Income Taxes [Line Items]
Year Expired	2033
Amount	$ 6,455,113
State [Member] | 2019 [Member]
Income Taxes [Line Items]
Year Expired	2034
Amount	$ 4,211,210
State [Member] | 2020 [Member]
Income Taxes [Line Items]
Year Expired	2035
Amount	$ 4,185,506
Australian [Member]
Income Taxes [Line Items]
Amount	$ 326,000
Australian [Member] | 2017 [Member]
Income Taxes [Line Items]
Year Expired	None
Amount
Australian [Member] | 2018 [Member]
Income Taxes [Line Items]
Year Expired	None
Amount	$ 290,490
Australian [Member] | 2019 [Member]
Income Taxes [Line Items]
Year Expired	None
Amount	$ 35,861

Commitments (Details Narrative)

Commitments (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)ft²	Dec. 31, 2019USD ($)
Leases payments, per month	$ 91,605	$ 89,574
Research and Development Expense [Member]
Lease expense	60,547	68,252
General and Administrative Expense [Member]
Lease expense	30,274	34,126
Operating Leases [Member]
Lease expense	$ 90,821	$ 102,378
Knoxville, Tennessee [Member]
Area of land | ft²	4,500
Lease term	5 years
Lease expiration date	Jun. 30, 2022
Leases payments, per month	$ 7,900

Commitments - Schedule of Right

Commitments - Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 91,605	$ 89,574
Right-of-use assets obtained in exchange for lease obligations: Operating leases		$ 265,550
Weighted Average Remaining Lease Term: Operating leases	1 year 6 months	2 years 9 months
Weighted Average Discount Rate: Operating leases	8.00%	8.00%

Commitments - Schedule of Futur

Commitments - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 92,471
2022	46,687
Total future minimum lease payments	139,158
Less: amount representing imputed interest	(9,992)
Total	$ 129,166

401(K) Profit Sharing Plan (Det

401(K) Profit Sharing Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Contributions to the 401(K) Profit Sharing Plan

Litigation (Details Narrative)

Litigation (Details Narrative) - Culpepper Employment Agreement [Member] - Peter Culpepper [Member] - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Damages sought to be receivable	$ 2,240,000
Litigation cost	227,750
Litigation reserve	$ 2,104,543	$ 2,104,543

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	2 Months Ended	12 Months Ended
	Mar. 02, 2021	Dec. 31, 2020	Dec. 31, 2019
Exercised price per share		$ 0.053	$ 0.053
Proceeds from exercise of warrants		$ 418,676	$ 268,943
Subsequent Event [Member]
Warrant to purchase common stock	4,500,000
Exercised price per share	$ 0.0533
Proceeds from exercise of warrants	$ 239,850
Subsequent Event [Member] | 2020 Note [Member] | Non-Related Party [Member]
Debt instrument, face amount	1,200,000
Proceeds from related party